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Objectives The aim of this study was to examine sex differences in outcome after transcatheter aortic valve replacement
(TAVR) with real-world data from 2 large centers in Canada.
Background Transcatheter aortic valve replacement is an effective alternative to surgical valve replacement in symptomatic pa-
tients with severe aortic stenosis, but the impact of sex on outcomes remains unclear. The PARTNER (Placement of
Aortic Transcatheter Valves) 1A trial demonstrated greater benefit of TAVR over surgery in women, but whether this
was due to the poorer surgical outcome of women or better TAVR outcome, compared with men, is unknown.
Methods Consecutive patients (n  641) undergoing TAVR in Vancouver and Quebec City, Canada, were evaluated. Differ-
ences in all-cause mortality were examined with Kaplan-Meier estimates, adjusted logistic regression, and pro-
portional hazards models.
Results Women comprised 51.3% of the cohort. Balloon-expandable valves were used in 97% of cases, with transapical ap-
proach in 51.7 % women and 38.1% men. Women had more major vascular complications (12.4% vs. 5.4%, p 
0.003) and borderline significantly more major/life-threatening bleeds (21.6% vs. 15.8%, p  0.08). At baseline,
women had higher aortic gradients and worse renal function but better ejection fractions. Men had more comorbidi-
ties: prior myocardial infarction, prior revascularization, and chronic obstructive pulmonary disease. The adjusted odds
ratio for 30-day all-cause mortality favored women, 0.39 (95% confidence interval: 0.19 to 0.80; p  0.01), and this
benefit persisted for 2 years, hazard ratio 0.60 (95% confidence interval: 0.41 to 0.88; p  0.008).
Conclusions Female sex is associated with better short- and long-term survival after TAVR. Added to the PARTNER 1A find-
ings, these results suggest TAVR might be the preferred treatment option for elderly women with symptomatic
severe aortic stenosis. (J Am Coll Cardiol 2012;60:882–6) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.009F
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FUntreated patients with symptomatic aortic stenosis (AS)
experience a high rate of death (1,2). Surgical aortic valve
replacement improves both symptoms and survival; but with
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2012, accepted May 11, 2012.advanced age, poor left ventricular function, or comorbid
conditions, operative mortality and complications can be
high (3,4). In such patients, transcatheter aortic valve
replacement (TAVR) is an effective alternative (5,6). How-
ever, the effect of sex on outcomes after TAVR remains
unclear. In the randomized PARTNER (Placement of
Aortic Transcatheter Valves) 1A trial, a pre-specified sub-
group analysis suggested the mortality benefit of TAVR over
surgical replacement at 1 year was greater in women (6).
urther examination of the data from the TAVR-only arm
emonstrates greater benefit in women but without adjustment
or potential baseline differences between women and men.
urther investigation of this potential benefit is warranted.
Three recent publications examined sex differences inutcomes after TAVR. A single-center study of 305 high-
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30-day mortality but a higher rate of vascular complications
and bleeding in women (7). Another study of 260 consec-
utive TAVR patients reported better 1-year survival in
women (8) but failed to adjust for baseline characteristics,
which varied substantially between men and women. A brief
report on sex differences in 333 consecutive patients with a
Medtronic CoreValve (Medtronic, Inc., Irvine, California)
found no sex differences in 30-day or 1-year mortality (9).
With limited and conflicting evidence of sex differences
in TAVR outcomes, we evaluated patients who underwent
TAVR in 2 high-volume centers in Canada.
Methods
Study cohort. Consecutive, high-risk patients with severe
AS undergoing TAVR between January 2005 and Septem-
ber 2011 at St. Paul’s Hospital (Vancouver, Canada; n 
468) and the Quebec Heart and Lung Institute (Quebec
City, Canada; n  199) were prospectively captured in a
database. All symptomatic patients with severe AS, at high
or prohibitive risk for conventional surgery, were selected
for TAVR after review by a dedicated heart team compris-
ing interventional cardiologists and cardiac surgeons. Ex-
clusions included unsuccessful TAVR (i.e., the valve could
not be implanted) (n  7) or transcatheter heart valve
implantation in an existing bioprosthetic valve (n  19).
The final cohort comprised 641 patients with successful
placement of a transcatheter heart valve in a native valve. All
patients provided written informed consent. Postoperative
assessment occurred at 1, 6, and 12 months and annually
thereafter.
TAVR procedure. The TAVR was performed with
balloon-expandable valves, Cribier-Edwards, Edwards
SAPIEN, Edwards SAPIEN XT (Edwards Lifesciences,
Inc., Irvine, California) and self-expanding valves (Core-
Valve, Medtronic Inc.; Portico, St. Jude Medical, St. Paul,
Minnesota; CENTERA, Edwards Lifesciences). Four valve
sizes were used: 20, 23, 26, and 29 mm. Transfemoral access
was the preferred route, except in patients with unsuitable
iliofemoral arteries.
Endpoints. The primary endpoints were 30-day all-cause
mortality and 2-year survival. Safety endpoints—vascular
complications, bleeds, stroke—were defined according to
the Valve Academic Research Consortium criteria (10).
Statistical analysis. Results are expressed as counts and
percentages for categorical variables and medians and 1st
and 3rd quartiles for continuous variables, due to skewed
distributions. Differences in baseline characteristics were
tested with the Mann-Whitney U test for continuous
ariables and the chi-square test for categorical variables.
Sex difference in survival was first evaluated with Kaplan-
eier curves. Multiple logistic regression analysis was used
o examine the independent sex effect on 30-day mortality.
ll clinically important variables were included in the
odel. In addition, variables unbalanced between men and
Aomen or with univariate analy-
is p values 0.25 for association
ith mortality were evaluated;
nd only those that improved the
odel fit, on the basis of the
kaike Information Criterion for
odel selection, were kept in the
nal fully adjusted model. A par-
imonious model was also built
rom the fully adjusted model
ith the backward elimination
ethod with p  0.10.
The association between sex and 2-year survival was exam-
ned with the Cox proportional hazards model. The propor-
ional hazard assumption was assessed by a Kolmogorov-type
upremum test. Multivariable Cox models were built in
Baseline CharacteristicsTable 1 Baseline Characteristics
Characteristic
Female
(n  329)
Male
(n  312) p Value
Age, yrs 83 (76, 87) 82 (76, 86) 0.55
STS-PROM score 7.5 (5, 10.2) 7.5 (4.8, 10.9) 0.76
AVA, cm2 0.6 (0.5, 0.7) 0.7 (0.6, 0.8) 0.001
AVA index, cm2/m2 0.35 (0.30, 0.43) 0.35 (0.30, 0.41) 0.36
Mean aortic gradient 41 (32, 53) 40 (30, 51) 0.01
Body surface area, m2 1.6 (1.5, 1.8) 1.9 (1.8, 2.0) 0.001
MR grade III/IV 99 (30.3) 67 (21.6) 0.01
AR grade III/IV 20 (6.2) 18 (5.8) 0.84
NYHA III/IV 287 (87.2) 267 (85.6) 0.54
EF 60 (55, 65) 55 (40, 60) 0.001
EF 0.001
30% 12 (3.6) 28 (9.1)
30% to 60% 87 (26.4) 140 (45.3)
60% 230 (69.9) 141 (45.6)
CAD 211 (64.1) 256 (82.6) 0.001
Prior MI 117 (35.8) 142 (45.5) 0.01
Prior revascularization 130 (39.5) 198 (63.5) 0.001
Atrial fibrillation 107 (32.5) 121 (38.9) 0.09
Heart failure 232 (70.7) 232 (74.4) 0.30
COPD 70 (21.3) 100 (32.1) 0.002
Cerebrovascular disease 52 (15.9) 66 (21.4) 0.07
Hypertension 264 (80.2) 242 (77.6) 0.41
Peripheral vascular disease 96 (29.3) 108 (35.8) 0.13
Diabetes 99 (30.1) 98 (31.4) 0.72
eGFR, ml/min 48 (36, 64) 53 (38, 69) 0.05
eGFR, 60 ml/min 103 (31.8) 125 (40.2) 0.03
Hemodialysis 5 (1.5) 11 (3.5) 0.10
Frailty 135 (41.3) 98 (31.6) 0.01
Porcelain aorta 92 (29.2) 37 (12.0) 0.001
Smoking 0.001
None 240 (72.9) 142 (45.5)
Remote 80 (24.3) 147 (47.1)
Current 9 (2.7) 23 (7.4)
Values are median (Q1, Q3) or n (%).
AR  aortic regurgitation; AVA  aortic valve area; CAD  coronary artery disease; COPD 
hronic obstructive pulmonary disease; EF  ejection fraction; eGFR  estimated glomerular
filtration rate; MI  myocardial infarction; MR  mitral regurgitation; NYHA  New York Heart
Abbreviations
and Acronyms
AS  aortic stenosis
AVA  aortic valve area
CI  confidence interval
EF  ejection fraction
HR  hazard ratio
TAVR  transcatheter
aortic valve replacementssociation functional class; STS-PROM score  Society
Mortality score.of Thoracic Surgeons Predicted Risk of
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and clinical factors as well as procedural complications on
the sex difference in survival.
A 2-sided p value of 0.05 was considered statistically
significant. Statistical analyses were performed with SAS soft-
ware (version 9.2, SAS, Cary, North Carolina).
Results
Women comprised 51.3% (n  329) of the final cohort.
There were no significant sex differences in age, Society of
Thoracic Surgeons Predicted Risk of Mortality (STS-PROM)
score, aortic valve area (AVA) index, aortic regurgitation
grade, and New York Heart Association functional class.
Women had higher mean aortic gradients, worse renal
function, and more porcelain aortas than men but better
ventricular function. Although women were more often
frail, the prevalence of most comorbid conditions was higher
in men, including coronary artery disease, prior myocardial
infarction, prior revascularization, and chronic obstructive
pulmonary disease (Table 1).
The balloon-expandable valves, Cribier-Edwards (9%),
Edwards SAPIEN (56%), and SAPIEN XT (32%) were
most commonly used. Larger valves (26 and 29 mm) were
deployed in more men (88.8%) than women (29.5%) (p 
0.001). More women (52%) than men (38%) had a transapi-
cal approach (p  0.001).
Improvements in AVA index and mean aortic gradient
after the procedure did not differ between the sexes. Mean
aortic gradient and left ventricular ejection fraction re-
mained higher in women (Table 2).
The 30-day rates of stroke and permanent pacemaker
implantation did not differ by sex (Table 3). Women had
more major/life-threatening bleeds (21.6% vs. 15.8%), more
blood transfusion (9.5% vs. 3.6%), and more major vascular
complications (12.4% vs. 5.4%).
More men (11.2%) than women (6.5%) died by 30 days
(p  0.05). After adjusting for aortic regurgitation grade
III/IV, mitral regurgitation grade III/IV, access route,
Functional Characteristics After Transcatheter Heart Valve ImplantTable 2 Functional Characteristics After Transcatheter Heart V
Characteristic n*
AVA 502
AVA index, cm2/m2 502
Change in AVA index 500
Mean aortic gradient 591
Change in mean aortic gradient 582
MR grade III/IV 616
AR grade III/IV 597
EF 612
30%
30% to 60%
60%
Values are median (Q1, Q3) or n (%). *Cases with non-missing values.
Abbreviations as in Table 1.estimated glomerular filtration rate, heart failure, chronicobstructive pulmonary disease, prior myocardial infarction,
coronary artery disease, STS-PROM score, AVA index,
mean aortic gradient, prior revascularization, porcelain
aorta, ejection fraction, and site, the female odds ratio for
30-day mortality was 0.39 (95% confidence interval [CI]:
0.19 to 0.80). In a parsimonious model, with only the first
5 covariates, the female odds ratio was 0.37 (95% CI: 0.19
to 0.72).
Median follow-up was 302 days (interquartile range: 44
to 712 days). The Kaplan-Meier survival curves demon-
strate a significant survival advantage for women, log-rank
test p 0.007 (Fig. 1). The 1- and 2-year survival estimates
were 82.7% (95% CI: 77.4% to 86.8%) and 72.1% (95% CI:
65.0% to 78.0%), respectively, for women and 72.5% (95%
CI: 66.4% to 77.7%) and 61.7% (95% CI: 54.1% to 68.3%),
respectively, for men.
In the Cox model for all-cause mortality up to 2 years, the
unadjusted hazard ratio (HR) for female sex was 0.64 (95%
CI: 0.46 to 0.88). The Cox model was then adjusted,
incrementally, for grouped baseline characteristics (Table 4).
After adjustment for age, site, and access route, the female
HR was 0.58 (95% CI: 0.41 to 0.82). After adding baseline
aortic valve characteristics (AVA index, mean gradient,
grade of regurgitation), STS-PROM score, and grade of
mitral regurgitation, the HR was 0.59 (95% CI: 0.42 to
0.84). Further adjustment for baseline comorbid conditions
gave an HR of 0.60 (95% CI: 0.41 to 0.88). After adding
Implantation
male Male p Value
.20, 1.60) 1.62 (1.40, 1.90) 0.001
.73, 1.00) 0.86 (0.74, 1.01) 0.43
.36, 0.63) 0.52 (0.39, 0.67) 0.21
, 14) 10 (7, 12) 0.003
43,22) 29 (41.5,20) 0.10
4.2) 41 (13.7) 0.86
.6) 9 (3.1) 0.24
0.001
.5) 22 (7.4)
5.1) 119 (40.1)
1.4) 156 (52.5)
30-Day Post-ProceduralComplications and OutcomesTable 3 30-Day Post-ProceduralComplications and Outcomes
Event
Total
(n  584)*
Female
(n  306)
Male
(n  278) p Value
Major vascular complication 53 (8.6) 38 (12.4) 15 (5.4) 0.003
Major/life-threatening bleed 110 (17.3) 66 (21.6) 44 (15.8) 0.08
Blood transfusion 39 (6.7) 29 (9.5) 10 (3.6) 0.005
Major stroke 11 (1.9) 6 (2.0) 5 (1.8) 0.89
New pacemaker 32 (5.5) 20 (6.4) 12 (4.3) 0.24
30-day mortality 51 (8.7) 20 (6.5) 31 (11.2) 0.05ationalve
Fe
1.40 (1
0.85 (0
0.49 (0
11 (8
31 (
45 (1
5 (1
11 (3
79 (2
225 (7Values are n (%). *Excluded 57 cases without 30 days of follow-up.
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threatening bleeding), the female HR was 0.55 (95% CI:
0.37 to 0.81; p  0.003).
Discussion
In a large cohort of elderly subjects undergoing TAVR for
severe AS, female sex was associated with significantly better
survival, both at 30 days and up to 2 years, even after
adjustment for demographic, procedural, and clinical factors.
In a finding consistent with other studies, women had
more vascular complications and major/life-threatening
bleeds. Yet despite these adverse events, all-cause mortality
remained lower in women.
The PARTNER 1A subgroup analysis demonstrated a
greater survival benefit with TAVR compared with surgery
in women (risk ratio: 0.68; 95% CI: 0.44 to 1.04) than men
(risk ratio: 1.17; 95% CI: 0.84 to 1.63), pinteraction  0.05.
Figure 1 Kaplan-Meier Plot for All-Cause Mortality
Women’s survival advantage at 30 days and throughout the 2-year follow-up period
Influence of Incremental Adjustmenton Cox M dels of F m e HR for MortalityTable 4 fluence of Incremental Adjustmenton Cox Models of Female HR for Mortality
Model HR* 95% CI p Value
Sex (unadjusted) 0.64 0.46–0.88 0.007
Model 1  age, access route, site 0.58 0.41–0.82 0.002
Model 2  STS-PROM, AVA index,
MR, AR, mean gradient
0.59 0.42–0.84 0.003
Model 3  eGFR, EF, AF, COPD,
prior MI, CAD, frailty
0.60 0.41–0.88 0.008
Model 4  major vascular complications,
major/life-threatening bleeding
complications
0.55 0.37–0.81 0.003
*Female versus male sex.c
AF  atrial fibrillation; CI  confidence interval; HR  hazard ratio; other abbreviations as in
able 1.ithin the TAVR arm, mortality was lower in women
18.4%) than men (28.4%) (p  0.03); after surgical valve
eplacement the rates for men (24.2%) and women (27.2%)
ere similar (p  0.54). Because there might be imbalances
n baseline characteristics between the sexes, the demon-
trated female advantage in the TAVR arm should be
onsidered suggestive rather than definitive.
Hayashida et al. (8) also reported better female survival
fter TAVR, but no adjustment was undertaken for sex
ifferences in baseline characteristics. In contrast to our
ndings and others (7), Hayashida et al. (8) did not find
ore major vascular events in women. Major/life-
hreatening bleeds were not reported. Of note, crude all-
ause mortality rates at 30 days were much higher than in
ur study: 17.8% versus 11.2% in men; 12.2% versus 6.5% in
omen.
It is unlikely the observed female advantage can be explained
y the observed baseline differences, given that extensive
djustment for demographic, procedural, and clinical differ-
nces failed to attenuate the sex difference. Sex has been shown
o impact cardiac remodeling and fibrosis (11,12). Specifically,
ardiac hypertrophy in patients with severe AS develops
ifferently in women than men. Interstitial fibrosis is more
ronounced in male hearts, as is collagen I, II, and matrix
etalloproteinase expression. Lower levels of fibrosis in
omen might underpin the more rapid reversal of myocardial
ypertrophy after correction of AS and might partially explain
he better outcome in women compared with men (13).
trengths and limitations. Comprehensive data collection
nd follow-up of TAVR patients at St. Paul’s Hospital and
he Quebec Heart and Lung Institute provided a rich.linical dataset that allowed us to adjust our models for
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cannot exclude the possibility of unmeasured confounders.
The study is limited to 2 large centers that predominately
used balloon-expandable devices. The results might not be
generalizable to other centers and other types of valves.
Conclusions
This is the largest study to date of sex differences in
outcomes after TAVR in the “real world.” Women had
significantly better survival, both short- and longer-term,
despite higher rates of major/life-threatening bleeding and
vascular complications. The results, when considered in the
context of the PARTNER 1A findings, suggest TAVR
might be the preferred mode of treatment in elderly women
with symptomatic severe AS.
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